SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron announced FDA and EMA acceptance of regulatory applications…

Regeneron Pharmaceuticals, Inc. · PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET

Regeneron announced FDA and EMA acceptance of regulatory applications for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG). The FDA granted Priority Review with a target action date in November 2026, and the EMA decision is expected in H2 2027. This is a significant pipeline catalyst for Regeneron, as cemdisiran could become the first siRNA approved for gMG with a convenient subcutaneous dosing schedule four times a year.

  • FDA accepted NDA for cemdisiran under Priority Review; target action date November 2026.
  • EMA accepted regulatory application; decision anticipated H2 2027.
  • Cemdisiran is an investigational siRNA targeting C5 for anti-AChR antibody-positive gMG.
  • Phase 3 NIMBLE trial data published in The Lancet and presented at AAN 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access